Researchers blend folk treatment, high tech for promising anti-cancer compound
Ancient wisdom, technological savvy -
Researchers at the University of Washington have blended the past with the present in the fight against cancer, synthesizing
a full of promise new put together from an ancient Chinese remedy that uses cancer cells’ insatiable appetite to save iron to create them a
target.
The substance, artemisinin, is derived from the wormwood plant and has been used in China since ancient times to treat
malaria. Earlier work by Henry Lai and Narendra Singh, both UW bioengineers, indicated that artemisinin alone could
selectively kill cancer cells while leaving normal cells unharmed.
The new multifaceted appears to greatly ameliorate that dull selectivity, according to a modish on that appeared in a latest issue
of the journal Life Sciences. In supplement to Lai and Singh, co-authors comprehend Tomikazu Sasaki and Archna Messay, both UW
chemists.
“By itself, artemisinin is take 100 times more selective in ruinous cancer cells as opposed to normal cells,” Lai said. “In
this bone up on, the new artemisinin put together was 34,000 times more strong in killing the cancer cells as opposed to their normal
cousins. So the tagging take care of appears to have greatly increased the potency of artemisinin’s cancer-destructive properties.”
The merge has been licensed to Chongqing Holley Holdings and Holley Pharmaceuticals, its U.S. subsidiary, to be developed
for practicable use in humans. Although the compound is reassuring, officials intend, hidden use for people is quieten years away.
In the enquiry, researchers exposed human leukemia cells and deathly white blood cells to the consolidation. While the leukemia cells
with dispatch died, the white blood cells remained essentially unharmed.
The trick to the compound’s effectiveness, according to Lai, appears to be in taking asset of how cancer cells function.
Because they multiply so rapidly, most cancer cells need more iron than usual cells to replicate DNA. To facilitate that,
cancer cells have inlets on their outwardly, known as transferrin receptors, in greater numbers than other cells. Those
receptors allow quick shipment into the cell of transferrin, an iron-carrying protein found in blood.
In creating the compound, researchers bound artemisinin to transferrin at the molecular level. The combination of the two
ingredients appears to a fast one on the cancer cell.
“We draft b call it a Trojan horse because the cancer apartment recognizes transferrin as a natural, non-venomous protein,” Lai said. “So the
cell picks up the compound without knowing that a bomb - artemisinin - is arcane inside.”
Once inside of the room, the artemisinin reacts with the iron, spawning highly reactive chemicals called “free radicals.” The
relaxed radicals attack other molecules and the cubicle membrane, breaking it apart and killing the cell.
According to Lai, that modify is what initially piqued his behoof in artemisinin about 10 years ago. The wormwood extract
was hand-me-down centuries ago in China, but the treatment became lost over time. In the 1970s, it was rediscovered as part of an
ancient manuscript containing medical remedies, including a system that used a wormwood extract. The medical community soon
discovered that the extract, artemisinin, worked well against malaria, and it is currently reach-me-down for that purpose throughout
Asia and Africa.
Artemisinin combats malaria because the malaria sponge collects high iron concentrations as it metabolizes hemoglobin in
the blood. As science began to understand how artemisinin functioned, Lai said, he began to admiration if the process had
implications notwithstanding cancer treatment.
“I started thoughtful that maybe we could use this intelligence to selectively target cancer cells,” he said. “So farther, the outlook
appears good.”
The next step in development under the Holley licensing agreement will likely be testing in animals and, if that pans out,
human trials to gauge the compound’s effectiveness. The current study was funded by the Artemisinin Check in Origination and
Chongqing Holley Holdings.
For more bumf, contact Lai at (206) 543-1071 or hlai@u.washington.edu. The Holley connection is Michael Liu at (714)
606-8415 or michael@holleypharma.com.
The article is available on-line at http://www.sciencedirect.com/science. Click the “journals” button and look under Vim Sciences, Volume
76, Issue 11. The article is No. 9 on the Web page (page 1267-1279).
Rob Harrill - rharrill@u.washington.edu
University of Washington